Application of metabolomics in Alzheimer's disease

Jordan Maximillian Wilkins, Eugenia D Trushina

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolomics is the newest omics platform that offers great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual's metabolome reflects alterations in genetic, transcript, and protein profiles and influences from the environment. Advancements in the field of metabolomics have demonstrated the complexity of dynamic changes associated with AD progression underscoring challenges with the development of efficacious therapeutic interventions. Defining systems-level alterations in AD could provide insights into disease mechanisms, reveal sex-specific changes, advance the development of biomarker panels, and aid in monitoring therapeutic efficacy, which should advance individualized medicine. Since metabolic pathways are largely conserved between species, metabolomics could improve the translation of preclinical research conducted in animal models of AD into humans. A summary of recent developments in the application of metabolomics to advance the AD field is provided below.

Original languageEnglish (US)
Article number719
JournalFrontiers in Neurology
Volume8
Issue numberJAN
DOIs
StatePublished - Jan 12 2018

Fingerprint

Metabolomics
Alzheimer Disease
Precision Medicine
Systems Biology
Metabolome
Genomics
Metabolic Networks and Pathways
Epigenomics
Neurodegenerative Diseases
Proteomics
Disease Progression
Therapeutics
Animal Models
Biomarkers
Research
Proteins

Keywords

  • Alzheimer's disease
  • Animal models of Alzheimer's disease
  • Biomarkers
  • Lipidomics
  • Metabolomics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Application of metabolomics in Alzheimer's disease. / Wilkins, Jordan Maximillian; Trushina, Eugenia D.

In: Frontiers in Neurology, Vol. 8, No. JAN, 719, 12.01.2018.

Research output: Contribution to journalReview article

@article{41b009f8b0d74d95a3df636481b3a92d,
title = "Application of metabolomics in Alzheimer's disease",
abstract = "Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolomics is the newest omics platform that offers great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual's metabolome reflects alterations in genetic, transcript, and protein profiles and influences from the environment. Advancements in the field of metabolomics have demonstrated the complexity of dynamic changes associated with AD progression underscoring challenges with the development of efficacious therapeutic interventions. Defining systems-level alterations in AD could provide insights into disease mechanisms, reveal sex-specific changes, advance the development of biomarker panels, and aid in monitoring therapeutic efficacy, which should advance individualized medicine. Since metabolic pathways are largely conserved between species, metabolomics could improve the translation of preclinical research conducted in animal models of AD into humans. A summary of recent developments in the application of metabolomics to advance the AD field is provided below.",
keywords = "Alzheimer's disease, Animal models of Alzheimer's disease, Biomarkers, Lipidomics, Metabolomics",
author = "Wilkins, {Jordan Maximillian} and Trushina, {Eugenia D}",
year = "2018",
month = "1",
day = "12",
doi = "10.3389/fneur.2017.00719",
language = "English (US)",
volume = "8",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
number = "JAN",

}

TY - JOUR

T1 - Application of metabolomics in Alzheimer's disease

AU - Wilkins, Jordan Maximillian

AU - Trushina, Eugenia D

PY - 2018/1/12

Y1 - 2018/1/12

N2 - Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolomics is the newest omics platform that offers great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual's metabolome reflects alterations in genetic, transcript, and protein profiles and influences from the environment. Advancements in the field of metabolomics have demonstrated the complexity of dynamic changes associated with AD progression underscoring challenges with the development of efficacious therapeutic interventions. Defining systems-level alterations in AD could provide insights into disease mechanisms, reveal sex-specific changes, advance the development of biomarker panels, and aid in monitoring therapeutic efficacy, which should advance individualized medicine. Since metabolic pathways are largely conserved between species, metabolomics could improve the translation of preclinical research conducted in animal models of AD into humans. A summary of recent developments in the application of metabolomics to advance the AD field is provided below.

AB - Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is halted by a lack of understanding early underlying pathological mechanisms. Systems biology encompasses several techniques including genomics, epigenomics, transcriptomics, proteomics, and metabolomics. Metabolomics is the newest omics platform that offers great potential for the diagnosis and prognosis of neurodegenerative diseases as an individual's metabolome reflects alterations in genetic, transcript, and protein profiles and influences from the environment. Advancements in the field of metabolomics have demonstrated the complexity of dynamic changes associated with AD progression underscoring challenges with the development of efficacious therapeutic interventions. Defining systems-level alterations in AD could provide insights into disease mechanisms, reveal sex-specific changes, advance the development of biomarker panels, and aid in monitoring therapeutic efficacy, which should advance individualized medicine. Since metabolic pathways are largely conserved between species, metabolomics could improve the translation of preclinical research conducted in animal models of AD into humans. A summary of recent developments in the application of metabolomics to advance the AD field is provided below.

KW - Alzheimer's disease

KW - Animal models of Alzheimer's disease

KW - Biomarkers

KW - Lipidomics

KW - Metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85040456972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040456972&partnerID=8YFLogxK

U2 - 10.3389/fneur.2017.00719

DO - 10.3389/fneur.2017.00719

M3 - Review article

VL - 8

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - JAN

M1 - 719

ER -